A Phase 4 interventional study of Pegloticase with MTX in Chronic Uncontrolled Gout, Gout and Uncontrolled Gout, sponsored by Amgen. Completed at 39 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-20.
Sponsored by Amgen · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing pegloticase in Gout — 1 open to participants now, 1 under way, 1 of them phase 3. Pegloticase · Gout.
Among the 14 studies testing pegloticase in Gout, this one is the 4th largest by enrollment, is the only one that started in 2020, is one of 7 in phase 4, and was the 10th registered.
347 studies on the registry are indexed under Gout; 49 are open to participants now.
Browse Gout studies →1 of the 14 studies testing pegloticase in Gout is open now, in 2 countries. Recruiting first, the newest first:
Amgen · Sites in United States, Puerto Rico
Ages 18+
By country, each count listing its studies:
Pegloticase: first FDA approval 2010 (KRYSTEXXA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 30 Gout studies recruiting now, 14 (47%) set no upper age limit and 10 (33%) stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 191 is above the median of 83 across 286 interventional studies indexed under Gout.
Median enrollment 93 across the 14 interventional studies. Of the 13 that completed or were terminated, 11 (85%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 14 have an industry lead sponsor. The 4 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Amgen has 9 studies filed under Gout — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing pegloticase in Gout, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety, tolerability and efficiency of pegloticase administered with a shorter infusion duration in participants with uncontrolled gout receiving methotrexate.
Approximately 180 participants will be enrolled. After a 4-week methotrexate run-in period, participants will be treated for up to 24 weeks with weekly oral methotrexate and biweekly 8mg pegloticase infusions. Up to three pegloticase infusion durations will be assessed in the study: 60-minute infusion, 45-minute infusion and 30-minute infusion. Safety evaluations will be performed regularly throughout the course of the study.
Acquired from Horizon in 2024.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Uncontrolled gout, defined as meeting the following criteria:
Symptoms of gout including at least 1 of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pegloticase 60 Minute Infusion with methotrexate (MTX). Participants will receive MTX (15 mg) (weekly) during the Run-in Period, then pegloticase (every 2 weeks) with MTX (weekly) for 24 weeks
Biological: Pegloticase with MTX
Pegloticase 45 Minute Infusion with methotrexate (MTX). Participants will receive MTX (15 mg) (weekly) during the Run-in Period, then pegloticase (every 2 weeks) with MTX (weekly) for 24 weeks
Biological: Pegloticase with MTX
Pegloticase 30 Minute Infusion with methotrexate (MTX). Participants will receive MTX (15 mg) (weekly) during the Run-in Period, then pegloticase (every 2 weeks) with MTX (weekly) for 24 weeks
Biological: Pegloticase with MTX
Drug pages: Pegloticase · Methotrexate
Participants will receive MTX during the run-in period then pegloticase with MTX for up to 24 weeks during the treatment period
Also known as: Methotrexate
Percentage of Participants Who Experienced an Infusion Reaction (IR), Including Anaphylaxis, Related to Pegloticase From Day 1 to Week 24
IRs, including anaphylaxis, were assessed after each infusion for a period of 24 weeks. IRs were defined as any infusion-related adverse event (AE) or cluster of temporally-related AEs, not attributable to another cause, which occurred during the pegloticase infusion and up to 2 hours post-infusion. Additional AEs occurring outside of the 2-hour window following infusion could also be categorized as an IR at the Principal Investigator's discretion.
Time frame: Day 1 to Week 24
Percentage of Serum Uric Acid (sUA) Responders at Month 6
Responders were defined as participants who achieved and maintained sUA levels below 6 mg/dL for at least 80% of the time during month 6. Responders who met sUA discontinuation criteria (2 consecutive sUA \> 6 mg/dL), regardless of treatment status were considered non-responders.
Time frame: Up to 6 months
Percentage of Participants Who Experienced an IR Leading to Discontinuation of Treatment, Anaphylaxis or Met sUA Discontinuation Criteria
IRs were defined as any infusion-related AE or cluster of temporally-related AEs, not attributable to another cause, which occurred during the pegloticase infusion and for 2 hours post-infusion. Other AEs that occurred outside of the 2 hour window following the infusion may have also been categorized as an IR at the Principal Investigator's discretion. Anaphylaxis was defined using the National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network criteria. Meeting individual sUA discontinuation criteria was defined as two consecutive pre-infusion sUAs \> 6 mg/dL after Day 1.
Time frame: Day 1 to Week 24
Time to First Event of IR Leading to Discontinuation of Treatment, Anaphylaxis or Meeting sUA Discontinuation Criteria in All Participants
Infusion reactions were defined as any infusion-related adverse event or cluster of temporally-related adverse events, not attributable to another cause, which occurred during the infusion and for 2 hours post-infusion. Other adverse events that occurred outside of the 2-hour window following the infusion may have also been categorized as an infusion reaction at the Principal Investigator's discretion. Anaphylaxis was defined using the National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network criteria. Meeting individual serum uric acid discontinuation criteria was defined as two consecutive pre-infusion serum uric acid levels greater than 6 mg/dL after Day 1. Time to event was derived as the date of the event minus the date of the first dose of the treatment plus 1. All participants were censored at the date of their last infusion.
Time frame: Day 1 to Week 24
Time to First Event of IR Leading to Discontinuation of Treatment, Anaphylaxis or Meeting sUA Discontinuation Criteria in Participants With an Event
IRs were defined as any infusion-related adverse event or cluster of temporally-related adverse events, not attributable to another cause, which occurred during the infusion and for 2 hours post-infusion. Other adverse events that occurred outside of the 2-hour window following the infusion may have also been categorized as an infusion reaction at the Principal Investigator's discretion. Anaphylaxis was defined using the National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network criteria. Meeting individual serum uric acid discontinuation criteria was defined as two consecutive pre-infusion serum uric acid levels greater than 6 mg/dL after Day 1. Time to event was derived as the date of the event minus the date of the first dose of the treatment plus 1. Only participants who experienced an event were included in this analysis.
Time frame: Day 1 to Week 24
Participants with uncontrolled gout were enrolled at 36 centers across the United States between October 2020 and March 2024.
| Milestone | Pegloticase 60 Minute + MTX | Pegloticase 45 Minute + MTX | Pegloticase 30 Minute + MTX |
|---|---|---|---|
| Started | 116 | 13 | 62 |
| Completed | 96 | 12 | 50 |
| Not completed | 20 | 1 | 12 |
| Withdrew: Lost to follow-up | 3 | 0 | 4 |
| Withdrew: Withdrawal by subject | 17 | 1 | 8 |
IRs, including anaphylaxis, were assessed after each infusion for a period of 24 weeks. IRs were defined as any infusion-related adverse event (AE) or cluster of temporally-related AEs, not attributable to another cause, which occurred during the pegloticase infusion and up to 2 hours post-infusion. Additional AEs occurring outside of the 2-hour window following infusion could also be categorized as an IR at the Principal Investigator's discretion.
| Percentage of Participants | Pegloticase 60 Minute + MTX | Pegloticase 45 Minute + MTX | Pegloticase 30 Minute + MTX |
|---|---|---|---|
| Percentage of Participants Who Experienced an Infusion Reaction (IR), Including Anaphylaxis, Related to Pegloticase From Day 1 to Week 24 | 6.0 (2.5 to 12.0) | 0 (0.0 to 24.7) | 12.9 (5.7 to 23.9) |
Responders were defined as participants who achieved and maintained sUA levels below 6 mg/dL for at least 80% of the time during month 6. Responders who met sUA discontinuation criteria (2 consecutive sUA \> 6 mg/dL), regardless of treatment status were considered non-responders.
| Percentage of Participants | Pegloticase 60 Minute + MTX | Pegloticase 45 Minute + MTX | Pegloticase 30 Minute + MTX |
|---|---|---|---|
| Percentage of Serum Uric Acid (sUA) Responders at Month 6 | 67.2 (57.9 to 75.7) | 76.9 (46.2 to 95.0) | 56.5 (43.3 to 69.0) |
IRs were defined as any infusion-related AE or cluster of temporally-related AEs, not attributable to another cause, which occurred during the pegloticase infusion and for 2 hours post-infusion. Other AEs that occurred outside of the 2 hour window following the infusion may have also been categorized as an IR at the Principal Investigator's discretion. Anaphylaxis was defined using the National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network criteria. Meeting individual sUA discontinuation criteria was defined as two consecutive pre-infusion sUAs \> 6 mg/dL after Day 1.
| Percentage of Participants | Pegloticase 60 Minute + MTX | Pegloticase 45 Minute + MTX | Pegloticase 30 Minute + MTX |
|---|---|---|---|
| Percentage of Participants Who Experienced an IR Leading to Discontinuation of Treatment, Anaphylaxis or Met sUA Discontinuation Criteria | 19.0 (12.3 to 27.3) | 7.7 (0.2 to 36.0) | 32.3 (20.9 to 45.3) |
Infusion reactions were defined as any infusion-related adverse event or cluster of temporally-related adverse events, not attributable to another cause, which occurred during the infusion and for 2 hours post-infusion. Other adverse events that occurred outside of the 2-hour window following the infusion may have also been categorized as an infusion reaction at the Principal Investigator's discretion. Anaphylaxis was defined using the National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network criteria. Meeting individual serum uric acid discontinuation criteria was defined as two consecutive pre-infusion serum uric acid levels greater than 6 mg/dL after Day 1. Time to event was derived as the date of the event minus the date of the first dose of the treatment plus 1. All participants were censored at the date of their last infusion.
| Days | Pegloticase 60 Minute + MTX | Pegloticase 45 Minute + MTX | Pegloticase 30 Minute + MTX |
|---|---|---|---|
| Time to First Event of IR Leading to Discontinuation of Treatment, Anaphylaxis or Meeting sUA Discontinuation Criteria in All Participants | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
IRs were defined as any infusion-related adverse event or cluster of temporally-related adverse events, not attributable to another cause, which occurred during the infusion and for 2 hours post-infusion. Other adverse events that occurred outside of the 2-hour window following the infusion may have also been categorized as an infusion reaction at the Principal Investigator's discretion. Anaphylaxis was defined using the National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network criteria. Meeting individual serum uric acid discontinuation criteria was defined as two consecutive pre-infusion serum uric acid levels greater than 6 mg/dL after Day 1. Time to event was derived as the date of the event minus the date of the first dose of the treatment plus 1. Only participants who experienced an event were included in this analysis.
| Days | Pegloticase 60 Minute + MTX | Pegloticase 45 Minute + MTX | Pegloticase 30 Minute + MTX |
|---|---|---|---|
| Time to First Event of IR Leading to Discontinuation of Treatment, Anaphylaxis or Meeting sUA Discontinuation Criteria in Participants With an Event | 17.0 (1 to 113) | 15.0 (15 to 15) | 43.0 (15 to 144) |
Collected over Up to approximately 1 year.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MTX Run-In | 0/215 (0%) | 1/215 (0.5%) | 79/215 (36.7%) |
| Pegloticase 60 Minute + MTX | 0/116 (0%) | 4/116 (3.4%) | 86/116 (74.1%) |
| Pegloticase 45 Minute + MTX | 0/13 (0%) | 0/13 (0%) | 13/13 (100%) |
| Pegloticase 30 Minute + MTX | 0/62 (0%) | 5/62 (8.1%) | 46/62 (74.2%) |
| Event | MTX Run-In | Pegloticase 60 Minute + MTX | Pegloticase 45 Minute + MTX | Pegloticase 30 Minute + MTX |
|---|---|---|---|---|
| Non-cardiac chest painGeneral disorders | 0/215 | 0/116 | 0/13 | 1/62 |
| Anaphylactic reactionImmune system disorders | 0/215 | 0/116 | 0/13 | 1/62 |
| Infusion related reactionInjury, poisoning and procedural complications | 0/215 | 1/116 | 0/13 | 1/62 |
| GoutMetabolism and nutrition disorders | 0/215 | 0/116 | 0/13 | 1/62 |
| ShockVascular disorders | 0/215 | 0/116 | 0/13 | 1/62 |
| Vertigo positionalEar and labyrinth disorders | 0/215 | 1/116 | 0/13 | 0/62 |
| Small intestinal obstructionGastrointestinal disorders | 0/215 | 1/116 | 0/13 | 0/62 |
| COVID-19Infections and infestations | 0/215 | 1/116 | 0/13 | 0/62 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 0/215 | 1/116 | 0/13 | 0/62 |
| GastroenteritisInfections and infestations | 1/215 | 0/116 | 0/13 | 0/62 |
| Event | MTX Run-In | Pegloticase 60 Minute + MTX | Pegloticase 45 Minute + MTX | Pegloticase 30 Minute + MTX |
|---|---|---|---|---|
| GoutMetabolism and nutrition disorders | 72/215 | 77/116 | 9/13 | 44/62 |
| DiarrhoeaGastrointestinal disorders | 3/215 | 3/116 | 2/13 | 4/62 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/215 | 4/116 | 2/13 | 2/62 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/215 | 3/116 | 2/13 | 2/62 |
| Infusion related reactionInjury, poisoning and procedural complications | 0/215 | 6/116 | 0/13 | 7/62 |
| COVID-19Infections and infestations | 2/215 | 4/116 | 0/13 | 6/62 |
| Lacrimation increasedEye disorders | 1/215 | 0/116 | 1/13 | 0/62 |
| Abdominal painGastrointestinal disorders | 0/215 | 0/116 | 1/13 | 2/62 |
| VomitingGastrointestinal disorders | 1/215 | 0/116 | 1/13 | 2/62 |
| HepatotoxicityHepatobiliary disorders | 0/215 | 0/116 | 1/13 | 0/62 |
Modified intent-to-treat (mITT) Analysis Set: All participants who received at least 1 dose of pegloticase.
| Age, Continuous(Years) | Pegloticase 60 Minute + MTX | Pegloticase 45 Minute + MTX | Pegloticase 30 Minute + MTX | Total |
|---|---|---|---|---|
| Mean | 55.2 ± 11.33 | 61.1 ± 9.96 | 56.9 ± 11.04 | 56.2 ± 11.20 |
| Sex: Female, Male(Participants) | Pegloticase 60 Minute + MTX | Pegloticase 45 Minute + MTX | Pegloticase 30 Minute + MTX | Total |
|---|---|---|---|---|
| Female | 12 | 2 | 9 | 23 |
| Male | 104 | 11 | 53 | 168 |
| Race/Ethnicity, Customized(Participants) | Pegloticase 60 Minute + MTX | Pegloticase 45 Minute + MTX | Pegloticase 30 Minute + MTX | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 1 |
| Asian | 8 | 1 | 2 | 11 |
| Black or African American | 18 | 3 | 9 | 30 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 1 |
| White | 84 | 9 | 48 | 141 |
| More than 1 race | 3 | 0 | 1 | 4 |
| Other | 3 | 0 | 0 | 3 |
| Race/Ethnicity, Customized(Participants) | Pegloticase 60 Minute + MTX | Pegloticase 45 Minute + MTX | Pegloticase 30 Minute + MTX | Total |
|---|---|---|---|---|
| Hispanic or Latino | 29 | 1 | 4 | 34 |
| Not Hispanic or Latino | 87 | 12 | 58 | 157 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Oct 2020 to primary completion in Jan 2024, 39 months.
Results were first posted in Jan 2025, 11 months after primary completion.
Of 18 phase 4 interventional studies under Gout, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's 39 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pegloticase · Methotrexate